Prof. Baosheng Li 李宝生
Chief Physician, Professor
Department of Thoracic Radiation Oncology I, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions:Vice President, Shandong Cancer Hospital
Checked against a public report (检索 2026-11-15). Positions change; the hospital's website is the final word.
Clinical focus: Tumor diagnosis and radiation therapy, including precise radiotherapy, comprehensive treatment, breast-conserving therapy, and stereotactic radiosurgery.
Dr. Li holds a PhD in Oncology and serves as Deputy Director and Chief of the Sixth Radiotherapy Department. Trained at Binzhou Medical College, Shandong Academy of Medical Sciences, and Southeast University, Dr. Li was a visiting professor at the University of Maryland (1999–2000). Research focuses on precise radiotherapy and organ motion management. Dr. Li has published over 140 papers and received two National Science and Technology Progress Awards.
Professional roles
- Standing Committee Member, Chinese Medical Association
- Vice Chair, Youth Committee on Tumor Radiotherapy, Chinese Medical Association
- Member, Tumor Radiotherapy Professional Committee, China Anti-Cancer Association
- Editorial Board Member, Chinese Journal of Radiological Medicine and Protection
Name order: in Chinese the family name comes first (Li Baosheng). Papers usually list the name as Baosheng Li or Li B.
Selected publications
215 papers on PubMed matched by name and affiliation; 111 as first or senior author since 2016. Most recent first- or senior-author papers:
- Radiother Oncol, 2026 (senior author): Single-cell and spatial transcriptomics delineate the remodeling of esophageal squamous-cell carcinoma ecosystem following diverse therapies. PubMed 42551634
- Future Oncol, 2026 (senior author): Efficacy analysis of first-line chemoimmunotherapy with or without radiotherapy in stage IVB esophageal squamous cell carcinoma: a real-world study. PubMed 42504461
- Int J Radiat Oncol Biol Phys, 2026 (senior author): Corrigendum to 'A Phase 1b Clinical Trial of Neoadjuvant Radio-immunotherapy for Esophageal Squamous Cell Cancer '[International Journal of Radiation Oncology*Biology*Physics Volume 119, Issue 3, 1 July 2024, Pages 896-901]. PubMed 42530499
- J Cancer Res Ther, 2025 (senior author): CT-based delta-radiomics nomogram for predicting post-neoadjuvant chemoradiotherapy lymph node metastasis in esophageal squamous cell carcinoma: A feasibility study. PubMed 41474247
- Front Oncol, 2025 (senior author): Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC. PubMed 41383503
- Med Biol Eng Comput, 2025 (senior author): Multi-task and multi-scale attention network for lymph node metastasis prediction in esophageal cancer. PubMed 40488960
- Discov Oncol, 2025 (senior author): The immune infiltration and prognostic significance of complement and coagulation cascade-related genes in lung adenocarcinoma. PubMed 41160214
- Discov Oncol, 2025 (senior author): Pilot research on predicting the sub-volume with high risk of tumor recurrence inside peritumoral edema using the ratio-maxiADC/meanADC from the advanced MRI. PubMed 40993281
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion